Lofexidine

Lofexidine
Clinical data
Trade names	Britlofex, Lucemyra, others
AHFS/Drugs.com	Monograph
Routes of; administration	By mouth
ATC code	N07BC04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	>90%
Protein binding	80–90%
Metabolism	Liver (glucuronidation)
Elimination half-life	11 hours
Excretion	Kidney
Identifiers
	IUPAC name (RS)-2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole;
CAS Number	31036-80-3 ;
PubChem CID	30668;
DrugBank	DB04948 ;
ChemSpider	28460 ;
UNII	UI82K0T627;
KEGG	D08141 ;
ChEBI	CHEBI:51368 ;
ChEMBL	ChEMBL17860 ;
CompTox Dashboard (EPA)	DTXSID7023221 ;
Chemical and physical data
Formula	C11H12Cl2N2O
Molar mass	259.13 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES Clc2c(OC(C/1=N/CCN\1)C)c(Cl)ccc2;
	InChI InChI=1S/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15) ; Key:KSMAGQUYOIHWFS-UHFFFAOYSA-N ;
	(what is this?) (verify)

Lofexidine, sold under the brand name Lucemyra among others,^[1] is a medication historically used to treat high blood pressure; today, it is more commonly used to help with the physical symptoms of opioid withdrawal.^[2] It is taken by mouth.^[3] It is an α_2A-adrenergic receptor agonist.^[3] It was approved for use by the Food and Drug Administration in the United States in 2018,^[3] considering it to be a first-in-class medication.^[4]

^ Cite error: The named reference FDA Approval was invoked but never defined (see the help page).
^ Cite error: The named reference BNF was invoked but never defined (see the help page).
^ ^a ^b ^c "FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults". U.S. Food and Drug Administration (FDA) (Press release). Archived from the original on September 2, 2019. Retrieved 18 May 2018.
^ New Drug Therapy Approvals 2018. U.S. Food and Drug Administration (FDA) (Report). January 2019. Archived from the original (PDF) on August 26, 2019. Retrieved 16 September 2020.

[FDA_Approval-1] Cite error: The named reference FDA Approval was invoked but never defined (see the help page).

[BNF-2] Cite error: The named reference BNF was invoked but never defined (see the help page).

[FDA2018-3] "FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults". U.S. Food and Drug Administration (FDA) (Press release). Archived from the original on September 2, 2019. Retrieved 18 May 2018.

[4] New Drug Therapy Approvals 2018. U.S. Food and Drug Administration (FDA) (Report). January 2019. Archived from the original (PDF) on August 26, 2019. Retrieved 16 September 2020.

[1]

[2]

[3]

[4]